Abstract
The pharmacokinetic parameters disposition half-life, metabolic clearance, volume of distribution, intrinsic clearance of unbound drug, and (distributive tissue volume/unbound fraction in tissue) were compared for 12 benzodiazepines in dog and man. With the exception of volume of distribution, statistically significant correlations were obtained when parameters were plotted on a double logarithmic grid. In general, benzodiazepines were metabolized more rapidly and exhibited greater tissue distribution in dog than in man. The variability in parameters was such, however, as to make extrapolations from one species to another subject to considerable error.
Similar content being viewed by others
References
B. B. Brodie and R. P. Maickel. Comparative biochemistry of drug metabolism. In B. B. Brodie and E. G. Erdös (eds.),Metabolic Factors Controlling Duration of Drug Action, Vol. 6, Proc. 1st International Pharmacology Meeting. Pergamon Press, Elmsford, N.Y., 1962, pp. 299–324.
J. J. Burns. Species differences and individual variations in drug metabolism. In B. B. Brodie and E. G. Erdös (eds.),Metabolic Factors Controlling Duration of Drug Action, Vol. 6, Proc. 1st International Pharmacology Meeting. Pergamon Press, Elmsford, N.Y., 1962, pp. 277–288.
B. B. Brodie. Difficulties in extrapolating data on metabolism of drugs from animal to man. Part VI.Clin. Pharmacol. Ther. 3:374–380 (1962).
J. N. Smith. Comparative biochemistry of detoxification. In M. Florkin and H. S. Mason (eds.),Comparative Biochemistry, A Comprehensive Treatise, Vol. VI, Cells and Organisms, Academic Press, New York, 1964, Chap. 8, pp. 403–457.
B. B. Brodie. Of mice, microsomes and man.Pharmacologist 6:12–26 (1964).
R. T. Williams. Comparative patterns of drug metabolism.Fed. Proc. 26:1029–1039 (1967).
L. B. Mellett. Comparative drug metabolism.Progr. Drug Res. 13:136–169 (1969).
H. B. Hucker. Species differences in drug metabolism.Annu. Rev. Pharmacol. 10:99–118 (1970).
R. L. Dedrick, K. B. Bischoff, and D. S. Zaharko. Interspecies correlation of plasma concentration history of methotrexate.Cancer Chemother. Rep. Part 1 54:95–101 (1970).
R. H. Adamson and D. S. Davies. Comparative aspects of absorption, distribution, metabolism and excretion of drugs. In M. J. Michelson (section ed.),International Encyclopedia of Pharmacology and Therapeutics, Sec. 85,Comparative Pharmacology. Pergamon Press, Oxford, 1973, Chap. 9, pp. 851–911.
R. L. Dedrick. Animal scale-up.J. Pharmacokin. Biopharm. 1:435–461 (1973).
G. P. Quinn, M. J. Hurwic, and J. H. Perel. Interspecies differences in drug metabolism. In E. Usdin and I. S. Forrest (eds.),Psychotherapeutic Drugs, Part 1, Principles, Marcel Dekker, New York, 1976, Chap. III-12, pp. 605–623.
B. Testa and P. Jenner.Drug Metabolism: Chemical and Biochemical Aspects, Marcel Dekker, New York, 1976, Chap. 2.3, pp. 361–417.
J. R. Gillette. Application of pharmacokinetic principles in the extrapolation of animal data to humans.Clin. Toxicol. 9:709–722 (1976).
U. Klotz, K.-H. Antonin, and P. R. Bieck. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig, and rat.J. Pharmacol. Exp. Ther. 199:67–73 (1976).
M. Weiss, W. Sziegoleit, and W. Förster. Dependence of pharmacokinetic parameters on the body weight.Int. J. Clin. Pharmacol. 15:572–575 (1977).
C. H. Walker. Species differences in microsomal monoxygenase activity and their relationship to biological half-lives.Drug Metab. Rev. 7:295–323 (1978).
J. R. Gillette. Extrapolations from microsomes to mice and men.Drug Metab. Dispos. 7:121–123 (1979).
C. H. Walker. Species variations in some hepatic microsomal enzymes that metabolize xenobiotics. In J. W. Bridges and L. F. Chasseaud (eds.),Progress in Drug Metabolism, Vol. 5. John Wiley & Sons, London, 1980, Chap. 2, pp. 113–164.
H. Boxenbaum. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin.J. Pharmacokin Biopharm. 8:165–176 (1980).
S. L. Lindstedt and W. A. Calder III. Body size, physiological time, and longevity of homeothermic animals.Q. Rev. Biol. 56:1–16 (1981).
H. Boxenbaum. Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics.J. Pharmacokin. Biopharm. 10:201–227 (1982).
R. R. Scheline. Metabolism of foreign compounds by gastrointestinal microorganisms.Pharmacol. Rev. 25:451–532 (1973).
W. A. Colburn, I. Bekersky, B. H. Min, B. J. Hodshon, and W. A. Garland. Contribution of gut contents, intestinal wall and liver to the first-pass metabolism of clorazepam in the rat.Res. Commun. Chem. Pathol. Pharmacol. 27:73–90 (1980).
Data on file. Hoffmann-LaRoche, Nutley, N.J.
S. A. Kaplan, J. A. F. de Silva, M. L. Jack, K. Alexander, N. Strojny, R. E. Weinfeld, C. V. Puglisi, and L. Weissman. Blood level profile in man following chronic oral administration of fiurazepam hydrochloride.J. Pharm. Sci. 62:1932–1935 (1973).
W. A. Mahon, T. Inaba, and R. M. Stone. Metabolism of flurazepam by the small intestine.Clin. Pharmacol. Ther. 22:228–233 (1977).
J. Rieder. Plasma levels and derived pharmacokinetic characteristics of unchanged nitrazepam in man.Arzn.-Forsch. 23:212–218 (1973).
J. Rieder and G. Wendt. Pharmacokinetics and metabolism of the hypnotic nitrazepam. In S. Garattini, E. Mussini, and L. O. Randall (eds.),The Benzodiazepines. Raven Press, New York, pp. 99–127.
C. M. Metzler, G. L. Elfring, and A. J. McEwen.A User's Manual for NONLIN and Associated Programs, Upjohn Co., Kalamazoo, Mich., April 20, 1974.
H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).
S. Riegelman, J. Loo, and M. Rowland. Concept of a volume of distribution and possible errors in evaluation of this parameter.J. Pharm. Sci. 57:128–133 (1968).
M. Rowland. Influence of route of administration on drug availability.J. Pharm. Sci. 61:70–74 (1972).
G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance.Clin. Pharmacol Ther. 18:377–390 (1975).
M. Rowland, T. F. Blaschke, P. J. Meffin, and R. L. Williams. Pharmacokinetics in disease states modifying hepatic and metabolic function. In L. Z. Benet (ed.),The Effect of Disease States on Drug Pharmacokinetics. Am. Pharm. Assoc., Acad. Pharm. Sci., Washington, D.C., 1976, Chap. 4, pp. 53–75.
M. Rowland and G. Tucker. Symbols in pharmacokinetics.J. Pharmacokin. Biopharm. 8:497–507 (1980).
P. L. Altman and D. S. Dittmer.Biology Data Book., Fed. Am. Soc. Exp. Biol., Washington, D.C., 1964, pp. 263–264.
J. W. Prothero. Scaling of blood parameters in mammals.Comp. Biochem. Physiol. 67A:649–657 (1980).
W. R. Stahl. Organ weights in primates and other mammals.Science 150:1039–1042 (1965).
S. A. Kaplan, M. L. Jack, R. E. Weinfeld, W. Glover, L. Weissman, and S. Cotler. Biopharmaceutic and clinical profile of bromazepam.J. Pharmacokin. Biopharm. 4:1–16 (1976).
J. Raaflaub and J. Speiser-Courvoisier. Zur pharmakokinetik von bromazepam beim menschen.Arzn.-Forsch. 24:1841–1844 (1974).
H. G. Boxenbaum, K. A. Geitner, M. L. Jack, W. R. Dixon, H. E. Spiegal, J. Symington, R. Christian, J. D. Moore, L. Weissman, and S. A. Kaplan. Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: single-dose studies by the intravenous, intramuscular and oral routes.J. Pharmacokin. Biopharm 5:3–23 (1977).
A. Berlin and H. Dahlström. Pharmacokinetics of the anticonvulsant drug clorazepam evaluated from single oral and intravenous doses and by repeated oral administration.Eur. J. Clin. Pharmacol. 9:155–159 (1975).
I. Bekersky, A. C. Massio, V. Mattaliano, H. G. Boxenbaum, E. D. Maynard, P. D. Cohn, and S. A. Kaplan. Influence of phenobarbital on the disposition of clonazepam and antipyrine in the dog.J. Pharmacokin. Biopharm. 5:507–512 (1977).
M. A. Schwartz, E. Postma, and Z. Gaut. Biological half-life of chlordiazepoxide and its metabolite, demoxypam, in man.J. Pharm. Sci. 60:1500–1503 (1971).
M. Rowland. Influence of route of administration on drug availability.J. Pharm. Sci. 61:70–74 (1972).
D. J. Greenblatt, M. D. Allen, J. S. Harmatz, and R. I. Shader. Diazepam disposition determinants.Clin. Pharmacol. Ther. 27:301–312 (1980).
H. G. Boxenbaum, H. N. Posmanter, T. Macasieb, K. A. Geitner, R. E. Weinfeld, J. D. Moore, A. Darragh, D. A. O'Kelley, L. Weissman, and S. A. Kaplan. Pharmacokinetics of flunitrazepam following single and multiple dose oral administration to healthy human subjects.J. Pharmacokin. Biopharm. 6:283–293 (1978).
M. Divoll and D. J. Greenblatt. Effect of age and sex on lorazepam protein binding.J. Pharm. Pharmacol. (in press).
D. M. Hailey and E. S. Baird. Plasma concentration of medazepam and its metabolites offer oral administration.Br. J. Anaesthesiol. 51:493–496 (1979).
U. Klotz, K. H. Antonin, H. Brügel, and P. R. Bieck. Disposition of diazepam and its major metabolite demethyl diazepam in patients with liver disease.Clin. Pharmacol. Ther. 21:430–436 (1977).
H. J. Shull, G. R. Wilkinson, R. Johnson, and S. Schenker. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.Ann. Int. Med. 84:420–425 (1976).
D. J. Greenblatt, M. Divoll, J. S. Harmat, and R. I. Shader. Oxazepam kinetics: effects of age and sex.J. Pharmacol. Exp. Ther. 215:86–91 (1980).
G. Alván, M. Jönsson, A. Sundwall, and J. Vessman. First pass conjugation and enterohepatic recycling of oxazepam in dogs; intravenous tolerance of oxazepam in propylene glycol.Acta Pharmacol. Toxicol. (Suppl. 1)40:16–27 (1977).
F. S. Eberts, Y. Philopoulos, L. M. Reineke, and R. W. Vliek. Triazolam disposition.Clin. Pharmacol. Ther. 29:81–93 (1981).
F. S. Eberts, Jr. Disposition of triazolam, 8-chloro-6-(0-chlorophenyl)-1-methyl-4H-Striazolo{4,3-a}{1,4}benzodiazepine in the dog.Drug Metab. Dispos. 5:547–555 (1977).
K. S. Pang and M. Rowland. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.J. Pharmacokin. Biopharm. 5:625–654 (1977).
K. S. Pang. Hepatic clearances of drugs and metabolites.Trends Pharmacol. Sci. (June, 1980), pp. 247–251.
K. S. Pang, personal communication.
S. A. Kaplan, unpublished observation.
W. A. Garland, Hoffmann-La Roche, Inc., personal communication.
R. W. Lucek and C. B. Coutinho. The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.Mol. Pharmacol. 12:612–619 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boxenbaum, H. Comparative pharmacokinetics of benzodiazepines in dog and man. Journal of Pharmacokinetics and Biopharmaceutics 10, 411–426 (1982). https://doi.org/10.1007/BF01065172
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01065172